Literature DB >> 27550852

Correction regarding data on blinatumomab-associated seizures.

Jacqueline B Stone1, Lisa M DeAngelis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27550852     DOI： 10.1038/nrclinonc.2016.134

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  5 in total

1.  Correction regarding data on blinatumomab-associated seizures.

Authors:  Max S Topp; Zachary Zimmerman; Hagop M Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

Review 2.  Cancer-treatment-induced neurotoxicity--focus on newer treatments.

Authors:  Jacqueline B Stone; Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2015-09-22       Impact factor: 66.675

3.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

Review 4.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

5.  Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.

Authors:  Hagop M Kantarjian; Anthony S Stein; Ralf C Bargou; Carlos Grande Garcia; Richard A Larson; Matthias Stelljes; Nicola Gökbuget; Gerhard Zugmaier; Jonathan E Benjamin; Alicia Zhang; Catherine Jia; Max S Topp
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.